Sequential targeted therapy for relapsed XXXX with all-trans @entity1968 and anti- @entity1116 monoclonal antibody M195.

@entity1 @entity2799 @entity137 @entity66 @entity2800 @entity49677 @entity3052 @entity1398 @entity1968 @entity1116
@entity2799 ( @entity2799 ) provides a model to examine the sequential use of selective oncogene product-targeted and lineage-targeted agents. @entity1968 (RA) has been shown to produce brief remissions by a novel differentiating mechanism in most @entity1 with @entity2799 . M195, a mouse monoclonal antibody (moAb) reactive with the cell-surface antigen @entity1116 , can target @entity2800 cells in @entity1 and reduce large leukemic burdens when labeled with 131I. We studied whether 131I-M195 could safely reduce minimal @entity66 and prolong remission and survival durations in @entity1 with relapsed @entity2799 after they had attained remission with all-trans RA. Seven @entity1 with relapsed @entity2799 in second remission were treated with either 70 (n = 2) or 50 (n = 5) mCi/m2 of 131I-M195. As a measure of minimal @entity66 , we serially monitored @entity49677 mRNA by a reverse transcription polymerase chain reaction (RT-PCR) assay. There was no immediate @entity137 . Late @entity137 was limited to myelosuppression, but no episodes of @entity1398 were seen. Six @entity1 had detectable @entity49677 mRNA after all-trans RA therapy; two had single negative RT-PCR determinations following 131I-M195. Median disease-free survival of the seven @entity1 was 8 months (range 3-14.5). Four @entity1 with median follow-up of 24 months remain alive, and median overall survival exceeds 21+ months (range 5.5-33+). This regimen based on targeted therapy compares favorably to other approaches for the treatment of relapsed @entity2799 , including that used in the immediately preceding trial in which @entity1 were induced into remission and maintained with all-trans RA, as well as other chemotherapy-based regimens. These data support further study of moAb-based therapy for minimal @entity66 in @entity3052 .
